-
Since the risk of gastrointestinal bleeding is increased when clopidogrel is added to aspirin therapy in patients with acute coronary syndromes (ACS), many prescribe proton-pump inhibitors (PPIs) to reduce this risk. However, mechanistic studies suggest that PPIs may reduce the effectiveness of clopidogrel.
-
Revascularization, in conjunction with optimal medical therapy, remains a critical component in therapy for patients with obstructive coronary artery disease (CAD).
-
Efforts to decrease door-to-balloon time for primary percutaneous intervention (PCI) in an acute ST elevation myocardial infarction (STEMI), may include preferential triage to hospitals expert in primary PCI, partly because of evidence suggesting better outcomes.
-
-
The optimal timing of surgery for asymptomatic severe mitral valve regurgitation (MR) is unclear. Thus, Kang et al from South Korea studied the outcomes of patients treated with early surgery to those treated more conservatively in a prospective observational study.
-
Dronedarone is a new antiarrhythmic drug with structural similarities to amiodarone.
-
The clinical utility of microvolt T-wave alternans (MWTA) testing to detect subtle beat-to-beat oscillations in the electrocardiogram's T-wave amplitude as a non-invasive method for predicting sudden cardiac death remains undetermined.
-
-
Individualization of therapy with pharmacogenetics; the rate vs rhythm debate; the FDA's Risk Evaluation and Mitigation Strategy; FDA actions.
-
Nucleic acid amplification (NAA) testing should be performed on at least one respiratory specimen from each patient with signs and symptoms of pulmonary TB for whom a diagnosis of TB is being considered but has not yet been established, and for whom the test result would alter case management or TB control activities.